Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency

Detalles Bibliográficos
Autores principales: Mungmunpuntipantip, Rujittika, Wiwanitkit, Viroj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608549/
https://www.ncbi.nlm.nih.gov/pubmed/34823756
http://dx.doi.org/10.1016/j.anai.2021.09.007
_version_ 1784602763873746944
author Mungmunpuntipantip, Rujittika
Wiwanitkit, Viroj
author_facet Mungmunpuntipantip, Rujittika
Wiwanitkit, Viroj
author_sort Mungmunpuntipantip, Rujittika
collection PubMed
description
format Online
Article
Text
id pubmed-8608549
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-86085492021-11-23 Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj Ann Allergy Asthma Immunol Correspondence American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2021-12 2021-11-23 /pmc/articles/PMC8608549/ /pubmed/34823756 http://dx.doi.org/10.1016/j.anai.2021.09.007 Text en © 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Mungmunpuntipantip, Rujittika
Wiwanitkit, Viroj
Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
title Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
title_full Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
title_fullStr Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
title_full_unstemmed Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
title_short Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
title_sort messenger rna vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608549/
https://www.ncbi.nlm.nih.gov/pubmed/34823756
http://dx.doi.org/10.1016/j.anai.2021.09.007
work_keys_str_mv AT mungmunpuntipantiprujittika messengerrnavaccinesandneutralizingantisevereacuterespiratorysyndromecoronavirus2antibodiesinpatientswithimmunodeficiency
AT wiwanitkitviroj messengerrnavaccinesandneutralizingantisevereacuterespiratorysyndromecoronavirus2antibodiesinpatientswithimmunodeficiency

Ejemplares similares